Renew the paradigm. Optimize our therapy.
Decades ago, a lot more doctors knew how thyroid hormone levels influenced all organs and tissues’ health. It wasn’t all about the influence of thyroid hormones on the TSH. It was more about the influence of truly adequate thyroid hormone levels on real health outcomes. A lot more doctors learned and understood that if thyroid …
Continue reading The loss of thyroid clinical knowledge from Werner & Ingbar’s The Thyroid
Part 1: Five historical voices say: "No, 25 mcg of L-T3 Liothyronine isn’t equivalent to 100 mcg L-T4" Part 2: Contemporary thyroid science: "L-T3 pharmaceutical equivalency, Part 2: New thyroid science" REFERENCES Pharmaceutical monographs Armour Thyroid web page: https://www.rxlist.com/armour-thyroid-drug.htm#description Erfa Thyroid monograph, page 8 https://pdf.hres.ca/dpd_pm/00034857.PDF Pfizer Cytomel monograph, page 12 https://www.pfizer.ca/sites/default/files/201710/Cytomel_PM.pdf Mylan Synthroid monograph, page …
Robert Utiger, M.D. (1931-2008) is well known in endocrinology as the father of the TSH test. Despite his trust in the TSH test, in his publications he acknowledged that TSH behaved very unnaturally in response to T3 levels in blood while dosing T3 thyroid medication. What Utiger discovered in the 1970s and 1980s about the …
Continue reading A Dialogue with Utiger: T3-based thyroid therapy over-suppresses TSH
In standard T4 thyroid therapy, TSH normalization is so easy to achieve that it is almost impossible to fail. First, TSH out of range is the judge of an initial DIAGNOSIS. Next, normal TSH becomes the sole TARGET of therapy. Finally, normal TSH becomes the sole JUDGE of therapy success. This is faulty reasoning. There …
Patients and doctors are often told there's an ideal "target" for TSH levels. Some believe that in thyroid therapy, your TSH should be below the upper reference limit, some say it should be below 2.5, and a minority will even say it should be suppressed entirely whether or not you are a thyroid cancer patient. …
Continue reading Targeting TSH? It’s not as specific or as sensitive as people claim.
I'd like to talk about contemporary researchers' rigid and limited approach to combination therapy. This is the model whose many limitations I point out with the ridiculously long label "mini-T3-mono-combination" therapy. I'll go over some of the history behind this model, the source of the rigid ratios that we learned about in our series on …
Continue reading The mini-T3-mono-combination therapy model vs NDT and others
In contrast with a long list of over 70 medical research articles on low T3 syndrome that excluded thyroid patients, I have only found three (3) studies so far that included patients being treated for hypothyroidism. I'll reveal their treasures and disappointments in reverse date order: Somppi, 2017 Tevaarwerk, 2014 Wadwekar, 2004 Here's how many …
Continue reading Low T3 syndrome in thyroid therapy: THREE studies
